Skip to content
Log in
Sponsored AI AM CLAUDE, A Beginner's Guide: Learn the basics of working with AI AI AM CLAUDE, A Beginner's Guide: Learn the basics of working with AI
Review

Diagnostic value of blood p-tau subtypes in Alzheimer’s disease progression and pathology: systematic review and meta-analysis

Peng Zhang De-Long Huang Xing-Yu Lu Hao-Shu Zhong Cheng-Zhen Liu Han-Yang Liu Xiao-Dong Duan Jun-Hao Wu
Aug 2026 · European Archives of Psychiatry and Clinical Neuroscience · Vol 276, pp. 3329 - 3341 · 0 citations · 47 references
Medicine

TL;DR

P-tau217 has poorer diagnostic performance in the stages of cognitive unimpaired or less cognitively impaired, especially in the Aβ positivity diagnosis of SCD and CU, which is consistent with the guidelines.

DOI PubMed Semantic Scholar
View source

Similar papers

Open access Jul 2026

Serum p-Tau217 and apolipoprotein E as potential biomarkers for Alzheimer's disease severity: a case-control study

Increased serum p-tau217 and decreased ApoE levels were significantly associated with greater AD severity, suggesting that both biomarkers may serve as complementary noninvasive indicators of disease severity in Alzheimer’s disease.

Ahmed Kadom Kalaf, Khawla A. Shemran, Waleed Azeez AlAmeedy · 0 citations
Review Open access Sep 2026

Plasma p-tau217/Aβ42 Ratio vs p-tau217 Alone in Alzheimer's Disease: A Systematic Review and Meta-Analysis

The plasma p-tau217/Aβ42 ratio functions as an effective first-line screening tool that resolves ambiguous cases, significantly decreases gray-zone classifications, and increases diagnostic confidence, but does not significantly enhance absolute diagnostic discrimination (AUC) relative to p-tau217 alone.

Adil Khan, Awais Ahmad, Usman Khan et al. · 0 citations
Review Open access Sep 2026

ALZHEIMER’S DISEASE - ETIOPATHOGENESIS, CLINICAL PRESENTATION, AND CURRENT DIAGNOSTIC METHODS - A LITERATURE REVIEW

Introduction: Alzheimer’s disease (AD) is the most common cause of dementia, accounting for 60–80% of cases, and its prevalence is increasing as the population ages. It is estimated that approximately 50 million people worldwide currently live with dementia, and this number could triple by 2050. AD is a chronic, progre...

Mateusz Cieciora, M. Kawiorska, Julia Surowiec et al. · 0 citations
Review Open access Aug 2026

PLASMA p-tau217 AS A MINIMALLY INVASIVE BIOMARKER FOR ALZHEIMER’S DISEASE DIAGNOSIS: ANALYTICAL PLATFORMS, DIAGNOSTIC PERFORMANCE, AND CLINICAL IMPLEMENTATION CHALLENGES

Plasma p-tau217 showed high diagnostic performance for identifying amyloid and tau pathology and generally outperformed other phosphorylated tau isoforms, but it should not be interpreted as a stand-alone test.

Oliwia Lenkiewicz, Julia Lenkiewicz, Z. Chmielewska et al. · 0 citations
Open access Aug 2026

Expression differences and diagnostic efficacy of core plasma biomarkers in Alzheimer’s disease, cerebral small vessel disease and healthy adults

Among patients with isolated AD or isolated CSVD, plasma p-Tau217 is the optimal specific biomarker for the diagnosis of AD and differentiation between AD and cerebral small vessel disease.

Xian-Dong Wang, Jun-Qiu Wu, Xuan Zhang et al. · 0 citations
Aug 2026

Cross-Sectional and Longitudinal Diagnostic Performance of Plasma p-tau217 and p-tau217/Aβ42 in Alzheimer's Disease.

OBJECTIVE Recent studies suggest that combining plasma phosphorylated tau (p-tau) with β-amyloid (Aβ) may improve diagnosis accuracy for Alzheimer's disease (AD). However, the cross-sectional and longitudinal concordance of these markers with Aβ positron emission tomography (PET) positivity remains incompletely underst...

Mingxing Jiang, Guo-Yu Lan, Jiayi Zhu et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.